News & Events about Newlink Genetics Corporation.
12th Annual Corporate Access Event
Register for in-person meetings with Lumos Pharma
AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.(NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2...
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Companys interim data from two Phase 2 ...
Ticker Report
2 months ago
Lumos Pharma (NASDAQ:LUMO Get Rating) had its price target decreased by Oppenheimer to $18.00 in a research note issued to investors on Thursday morning, Stock Target Advisor reports. Oppenheimer also issued estimates for Lumos Pharmas FY2022 earnings at ($3.71) EPS, Q2 2023 earnings ...
Lumos Pharma (NASDAQ:LUMO Get Rating) had its price target decreased by Oppenheimer to $18.00 in a research note issued to investors on Thursday morning, Stock Target Advisor reports. Oppenheimer also issued estimates for Lumos Pharmas FY2022 earnings at ($3.71) EPS, Q2 2023 earnings at ($1.06) EPS...
Globe Newswire
5 months ago
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.(NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on...